An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics

Tilden, Dominic; Aristides, M; Meddis, David; Burns, Tom

doi:10.1016/s0149-2918(02)80069-8

Cited by 22 publications

(26 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent models tend to be based on observed data from systematic reviews, clinical trials or large observational databases. 32,33,[153][154][155][156][157][158][159][160] However, most of the studies have been limited in scale and methodology. Particular issues of concern are first, that with the exception of RCTs, 73,[143][144][145][146][147]149,151,152 most of the studies do not use clear and adequate methods to control bias.…”

Section: The Economics Of Schizophreniamentioning

confidence: 99%

“…Nearly all the evaluations found that the new atypical antipsychotics were costeffective. 32,117,[130][131][132][133]135,137,139,141,[146][147][148]150,[152][153][154][155][157][158][159][160] The majority of comparisons of new atypical antipsychotics and conventional drugs considered risperidone or olanzapine. The systematic review and model by Bagnall and colleagues 32 considered a number of other new drugs in addition to these.…”

Section: The Economics Of Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Lewis

Davies²,

Jones³

et al. 2006

Health Technol Assess

135

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: SW Lewis received support for travel to meetings and honoraria for consultancies from AstraZeneca, Lilly, BristolMyersSquibb, Pfizer, Janssen, Wyeth, Lundbeck, GlaxoSmithKline and Novartis. L Davies received funding for preparing papers and attendance at meetings from Janssen, Hoechst Marion Roussel, Pfizer, AstraZeneca and Lundbeck, and project funding from Novartis. PB Jones received travel support to academic meetings from companies manufacturing drugs used in this study, and unrestricted use of honoraria and consultancy fees for some work for academic use in his department and elsewhere. TRE Barnes received travel support to academic meetings and honoraria for consultancy from companies manufacturing drugs used in this study, plus the award of a grant from Sanofi-Synthelabo for an investigator-initiated study. RM Murray received honoraria and advisory fees from pharmaceutical companies (paid into departmental research funds). R Kerwin received honoraria and advisory fees from pharmaceutical companies and received research grants for non-clinical research from Novartis. D Taylor received honoraria for a lecture and consultancy from manufacturers of atypical antipsy...

show abstract

Section: The Economics Of Schizophreniamentioning

confidence: 99%

Section: The Economics Of Schizophreniamentioning

confidence: 99%

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Lewis

Davies²,

Jones³

et al. 2006

Health Technol Assess

135

View full text Add to dashboard Cite

show abstract

“…It cost £244 less per patient over the 5-year period for the quetiapine-treated patients than for those treated with haloperidol (£38 106 v. £38 350). 29 However, these findings cannot be generalised to South Africa as substantial differences exist between psychiatric service delivery in the UK and both the private and public sectors in South Africa. Health care costs The results of the sensitivity analysis (not reported here) showed that quetiapine remains less costly than haloperidol in almost all cases under the baseline and private 1 situation.…”

Section: Resultsmentioning

confidence: 93%

“…29 Medical resource utilisation and unit costs were obtained for the South African private and public sec- …”

Section: The Pharmaco-economic Modelmentioning

confidence: 99%

Cost-effectiveness of an atypical conventional antipsychotic in South Africa: An economic evaluation of quetiapine versus haloperidol in the treatment of patients partially responsive to previous antipsychotics

Emsley

Booysen

2004

S. Afr. J. Psych.

View full text Add to dashboard Cite

Background. The introduction of a new generation of atypical antipsychotic agents has raised difficult economic and ethical questions, particularly in lower-income countries. The reported tolerability and efficacy advantages of the atypical antipsy- chotics over their conventional predecessors have to be weighed against their higher acquisition costs. Pharmaco-eco- nomic studies conducted in Western countries consistently report cost advantages or cost neutrality for these new agents. However, considerable differences in health care service pro- vision make it difficult to generalise these findings to South Africa.Method. We compared the direct costs (private and public sector) of treating schizophrenia with an atypical antipsychotic quetiapine, and with a conventional antipsychotic haloperidol, by adapting a decision-analytic pharmaco-economic model for South African circumstances. The sample comprised patients partially responsive to antipsychotics, who had partic- ipated in a multinational randomised controlled trial compar- ing the efficacy and safety of quetiapine versus haloperidol. Results. The estimated total direct cost for the treatment with quetiapine in South Africa was slightly less than for haloperidol for various models in both the private and the public sectors.Conclusions. Significant differences in health care provision make pharmaco-economic studies conducted in other coun- tries invalid for South African circumstances. Previously queti- apine treatment did not result in direct cost savings in South Africa. However, the recently introduced legislation to estab- lish single exit prices for medications has resulted in the cost of quetiapine treatment declining by 36.7% and that of haloperi- dol by 13%. This has translated into an overall direct cost sav- ing for quetiapine in both the private and public sector models. This, together with additional indirect advantages of the atypi- cal antipsychotics such as improved quality of life and better social and vocational functioning, argues strongly from both an economic and ethical perspective for the use of atypical antipsychotics in treating schizophrenia in South Africa.

show abstract

“…However, drug treatment constitutes only a small portion of the total costs, which may include such direct costs as hospitalization and such indirect costs as longterm social support. 17-2° Several of the atypical antipsychotic drugs, including olanzapine, 21 risperidone, 22 ziprasidone, 23 quetiapine, 24 and aripiprazole, 25 have demonstrated superiority to typical antipsychotics in maintaining response or preventing relapse in patients with schizophrenia. This reduction in relapses, and therefore fewer hospitalizations, 26 would be a cost benefit for patients taking atypical antipsychotic drugs.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study

Mačiulis

Bitter

Milasiunas³

et al. 2004

Current Therapeutic Research

View full text Add to dashboard Cite

show abstract

An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics

Cited by 22 publications

References 25 publications

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Cost-effectiveness of an atypical conventional antipsychotic in South Africa: An economic evaluation of quetiapine versus haloperidol in the treatment of patients partially responsive to previous antipsychotics

Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study

Contact Info

Product

Resources

About